Last reviewed · How we verify
Intratumoral Ipilimumab
At a glance
| Generic name | Intratumoral Ipilimumab |
|---|---|
| Also known as | Yervoy, BMS734016, MDX-010 |
| Sponsor | Providence Health & Services |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Chills
- Fatigue
- Pyrexia
- Nausea
- Rash
- Diarrhoea
- Headache
- Pruritus
- Vomiting
- Decreased appetite
- Hyperglycaemia
- Vision blurred
Key clinical trials
- Neo-adjuvant Immunotherapy in Patients With Localized Melanoma (PHASE2)
- A Phase I/II Clinical Trial on the Per-operative Intratumoral Administration of Myeloid Dendritic Cells Plus Ipilimumab and Nivolumab, Followed by Repeated Intracavitary Plus Intravenous Administration of Nivolumab in Patients With Recurrent Glioblastoma. (PHASE1, PHASE2)
- Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies (PHASE1)
- IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma (PHASE1, PHASE2)
- Ipilimumab for Head and Neck Cancer Patients (PHASE1)
- A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6 (PHASE1, PHASE2)
- An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers (PHASE1)
- Intratumoral Injection of Autologous CD1c (BDCA-1)+ MyDC, Avelumab, and Ipilimumab Plus Systemic Nivolumab (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intratumoral Ipilimumab CI brief — competitive landscape report
- Intratumoral Ipilimumab updates RSS · CI watch RSS
- Providence Health & Services portfolio CI